Ovid Therapeutics Inc. (OVID) News
Filter OVID News Items
OVID News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Latest OVID News From Around the Web
Below are the latest news stories about OVID THERAPEUTICS INC that investors may wish to consider to help them evaluate OVID as an investment opportunity.
Ovid Therapeutics to Present Five Abstracts Supporting its Epilepsy Programs at the 77th American Epilepsy Society Annual Meeting (2023)Posters with new preclinical data on the pharmacokinetic and pharmacodynamic behavior of OV329 support its profile as a potential best-in-class GABA aminotransferase inhibitor Disease models provide further evidence characterizing OV350 and its anticipated seizure reduction and neuroprotective profile, including its ability to reverse diazepam-resistant seizures NEW YORK, Dec. 01, 2023 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company developing medicines des |
Ovid Therapeutics (OVID) Upgraded to Buy: Here's WhyOvid Therapeutics (OVID) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. |
Q3 2023 Ligand Pharmaceuticals Inc Earnings CallQ3 2023 Ligand Pharmaceuticals Inc Earnings Call |
Ovid Therapeutics Inc (OVID) Reports Q3 2023 Financial ResultsCompany extends cash runway into 2026 and anticipates five clinical and regulatory milestones in the next 15 months |
Ovid Therapeutics Reports Third Quarter 2023 Financial Results and Corporate UpdatesReceived a $30 million payment from Ligand for the sale of a 13% interest in the potential future royalties and milestone payments owed to Ovid for soticlestat The Company extended its expected cash runway into 2026 Clinical trials studying soticlestat as a treatment for Lennox-Gastaut syndrome and Dravet syndrome remain on track; Takeda anticipates regulatory filings in its fiscal year 2024 Ovid recently hosted an R&D Day during which the Company announced indication and formulation expansions |
We're Not Very Worried About Ovid Therapeutics' (NASDAQ:OVID) Cash Burn RateEven when a business is losing money, it's possible for shareholders to make money if they buy a good business at the... |
These 2 ‘Strong Buy’ Penny Stocks Have Massive Upside Potential, Says OppenheimerLet’s talk about penny stocks. These are equities that trade for less than $5 per share, at the very bottom of the price range. While they are priced that low for a reason – and the reasons may vary – a low price in itself doesn’t mean that the stock’s fundamentals are sour. Smart investors can find some true bargains among penny stocks and set themselves up for outsized gains. The opportunity is linked to a simple question: Why is the company’s stock priced so low? If the answer is mainly benig |
Ovid Therapeutics and Ligand Pharmaceuticals Enter into a $30 Million Agreement for a 13% Interest in Soticlestat Royalties and Milestones Extending Ovid’s Cash Runway into 2026Ligand will receive 13% of all soticlestat royalties and milestone payments owed to OvidOvid secures a $30 million non-dilutive capital infusion from Ligand, which Ovid expects to extend its cash runway into 2026 while simultaneously retaining 87% of the interest in soticlestatTransaction provides further validation of soticlestat as a potential treatment for Lennox-Gastaut syndrome and Dravet syndrome NEW YORK and SAN DIEGO, Oct. 18, 2023 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID |
Ovid Therapeutics to Present at the Jefferies Biotech CNS/Neuro SummitNEW YORK, Oct. 10, 2023 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with epilepsies and seizure-related disorders, today announced that management will participate in a presentation at the Jefferies Inaugural Biotech CNS/Neuro Summit on Thursday, October 12, 2023, at 3:30 p.m. ET in New York. A live webcast of the Jefferies presentation can be accessed through the Events & Presentation |
20 Countries With Highest Rate of EpilepsyIn this article, we will take a detailed look at the 20 countries with the highest rates of epilepsy with insights into number of epilepsy cases by country and population. For a quick overview of 5 countries with high epilepsy rates, read our article 5 Countries with Highest Rate of Epilepsy. Epilepsy is a common neurological disorder […] |